Fomenko Y, Sirota V, Omarova I, Kabildina N, Amanov A
Karaganda State Medical University; Karaganda Regional Cancer Center, Kazakhstan.
Georgian Med News. 2017 Mar(264):11-16.
93 patients with LABC (T2N1-2M0, T3N0-2M0) at the age from 35 to 75 years were included in the trial. With 2 stage - 60 patients, with the third stage - 33 patients. All patients were randomized into 3 groups: The I control group (n=36) received 4 courses of neoadjuvant chemotherapy according to AC-protocol (doxorubicin 50 mg/m2, cyclophosphan-500 mg/m2 on day 1, repeated every three weeks) followed by radical mastectomy, 4 courses of adjuvant chemotherapy (АС), radiotherapy and hormone therapy if indicated. II investigative group (n=30) received the same CTX but in combination with Arglabin at a dose of 370 mg/m2 for 7 days. III investigative group (n=27) received Arglabin as monotherapy. The clinical efficacy of neoadjuvant chemotherapy according to the scheme of AC and AC + arglabin was the same and significantly exceeded Arlabine monotherapy. There was no statistically significant difference in pathological response in patients of all three groups. Arglabin has very low toxicity and eliminates the toxic effects of standard chemotherapy.
93例年龄在35至75岁之间的局部晚期乳腺癌（LABC，T2N1 - 2M0，T3N0 - 2M0）患者纳入试验。其中二期60例，三期33例。所有患者随机分为3组：I对照组（n = 36）按照AC方案接受4个疗程的新辅助化疗（多柔比星50 mg/m²，环磷酰胺500 mg/m²，第1天给药，每三周重复一次），随后行根治性乳房切除术，必要时进行4个疗程的辅助化疗（АС）、放疗和激素治疗。II研究组（n = 30）接受相同的环磷酰胺，但联合阿糖克拉滨，剂量为370 mg/m²，持续7天。III研究组（n = 27）接受阿糖克拉滨单药治疗。按照AC方案和AC + 阿糖克拉滨方案进行的新辅助化疗临床疗效相同，且显著超过阿糖克拉滨单药治疗。三组患者的病理反应无统计学显著差异。阿糖克拉滨毒性极低，可消除标准化疗的毒性作用。
